Arcturus Therapeutics Received Approval from Singapore Health Sciences Authority to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate and Provides New and Updated Clinical and Preclinical Data

… and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated … and gene editing therapeutics. Arcturus’ technologies are covered by its extensive … CALIFORNIA SINGAPORE UNITED STATES NORTH AMERICA ASIA PACIFIC INDUSTRY KEYWORD: BIOTECHNOLOGY FDA …